The mission of the Bioinformatics Shared Resource (BIC) is to provide Mayo Clinic Cancer Center (MCCC) members access to cutting-edge bioinformatics services and research collaborations through a highly experienced team of bioinformaticians. There are 4 categories of service lines offered by the BIC: 1) preprocessing of `omics' data using a suite of cutting-edge workflows; 2) exhaustive annotation services critical to the first-level interpretation of variants; 3) interpretation services (or tertiary analysis) involving pathway analysis; and 4) data-access services that provide centrally managed avenues to external data sources resources such as TCGA, GEO, and GTEX and to internal datasets (Mayo Clinic Biobank, Mayo Genomic Consortium), and genomics data-management solutions for large genomics projects. The BIC has made significant investments in developing the infrastructure to preprocess and interpret genomics data. With the help of Research IT, the bioinformatics technical team has implemented a comprehensive suite of workflows designed by and for faculty. This infrastructure is kept up to date by reviewing and integrating ?best of breed? open-source applications. When a workflow solution is not readily implementable from open-source applications, the BIC engage faculty in the design of novel methods. In addition to preprocessing workflows, applications have been developed to prioritize and filter variants and to visualize variants in the context of biological pathways, complementing a set of licensed commercial applications. Most importantly, the BIC has positioned itself as a bioinformatics research collaborator with MCCC members. BIC has representation at all 3 MCCC sites: Mayo Clinic in Rochester, MN (MCR); Mayo Clinic in Arizona (MCA); and Mayo Clinic in Florida (MCF). Over the last 5 years, BIC has supported more than 1240 projects for 176 MCCC members. During this period, BIC faculty were listed as key personnel on more than 60 submitted grants. Finally, BIC faculty and technical staff were co-authors of over 347 publications with MCCC members. BIC faculty are engaged in the Women's Cancer, Hematologic Malignancies and Gastrointestinal Cancer Programs and their associated Breast, Ovarian, Lymphoma, Multiple Myeloma, and Pancreatic SPOREs. The BIC has established close partnerships with the Genome Analysis Shared Resource and Biostatistics Shared Resource to provide effective and seamless support to MCCC members. The BIC has also partnered with the institution's Research IT resource to establish and maintain the infrastructure needs to manage genomics data and design optimized workflows.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113597
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications